Friday, March 14, 2008


i think we can all learn from (and read objectively) a recent study done on seretide (salmeterol/ fluticasone) and its benefits in the treatment of Chronic Obstructive Pulmonary Disease (COPD). nb consider that the study was supported by GlaxoSmithKline.

what is the TORCH survival study?

TORCH (TOwards a Revolution in COPD Health) is a multicentre, randomised, double-blind, parallel-group, placebo-controlled study. Approximately 6,200 patients with moderate-to-severe COPD were randomly assigned to b.i.d. treatment with either SFC (50/500 µg), fluticasone propionate (500 µg), salmeterol (50 µg) or placebo for 3 yrs. The primary end-point is all-cause mortality; secondary end-points are COPD morbidity relating to rate of exacerbations and health status, using the St George's Respiratory Questionnaire. Other end-points include other mortality and exacerbation end-points, requirement for long-term oxygen therapy, and clinic lung function. Safety end-points include adverse events, with additional information on bone fractures.

To simplify the findings, TORCH found that combination therapy with seretide :
  1. Improved survival (p=0.052 though, significance still debatable?)
  2. Improved lung function
  3. Increased quality of life (QOL)
  4. Increased likelihood of pneumonia, but did not increase pneumonia-related mortality.
today's symposium was interesting and quite insightful... though at some points it did feel like those wedding dinners where you hardly knew anyone (for me at least).

alright i'm really, really sleepy now. goodnight world!



Post a Comment

<< Home